D-ribofuranose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ribofuranose : A cyclic ribose having a 5-membered tetrahydrofuran ring; the predominant (C3'-endo) form of the two cyclic structures (the other is the "C2'-endo" form, having a 6-membered ring) adopted by ribose in aqueous solution. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID Source	ID
PubMed CID	5779
CHEMBL ID	444125
CHEBI ID	47013
SCHEMBL ID	27218

Synonyms (33)

Synonym
alpha-d-ribose-5
C00121
613-83-2
CHEBI:47013 ,
d-ribofuranose ,
smr000857325
MLS001335979
MLS001335980
AC-11298
R0025
(3r,4s,5r)-5-(hydroxymethyl)oxolane-2,3,4-triol
NCGC00247056-01
ribofuranose
CHEMBL444125
AKOS015918149
HMS2230E04
15761-67-8
EPITOPE ID:149136
SCHEMBL27218
alpha,beta-d-ribofuranose
HMFHBZSHGGEWLO-SOOFDHNKSA-N
AC-11299
AC-32439
ribofuranose (7ci,8ci,9ci)
ribofuranoside
rel-(3r,4s,5r)-5-(hydroxymethyl)tetrahydrofuran-2,3,4-triol
Q179271
d-ribofuranose (closed ring structure, relative stereochemistry)
DTXSID201317333
EN300-365473
d ribos
HY-113375
CS-0062320

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

Class	Description
ribofuranose	A cyclic ribose having a 5-membered tetrahydrofuran ring; the predominant (C3'-endo) form of the two cyclic structures (the other is the "C2'-endo" form, having a 6-membered ring) adopted by ribose in aqueous solution.
D-ribose	A ribose in which the chiral carbon atom furthest away from the aldehyde group (C4') has the same configuration as in D-glyceraldehyde.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (38)

Pathway	Proteins	Compounds
Metabolism	1496	1108
Carbohydrate metabolism	173	120
Pentose phosphate pathway	13	30
Regulation of leaf development	17	22
Pentose Phosphate Pathway	15	27
Glucose-6-phosphate Dehydrogenase Deficiency	15	27
Ribose-5-phosphate Isomerase Deficiency	15	27
Transaldolase Deficiency	15	27
Ribose Degradation	5	8
NAD Metabolism	14	35
AMP Degradation (Hypoxanthine Route)	4	13
cis-Zeatin-O-Glucoside Biosynthesis	3	13
cis-Zeatin-N-Glucoside Biosynthesis	3	14
Pentose phosphate cycle ( Pentose phosphate cycle )	22	25
Arsenate Detoxification	7	16
pyridine nucleotide cycling (plants)	0	22
caffeine biosynthesis I	0	12
caffeine biosynthesis II (via paraxanthine)	0	12
theobromine biosynthesis I	0	9
adenosine nucleotides degradation I	2	27
purine nucleotides degradation I (plants)	2	34
pyrimidine ribonucleosides salvage III	6	13
superpathway of pyrimidine ribonucleosides salvage	22	37
pyrimidine ribonucleosides salvage II	8	12
guanine and guanosine salvage II	2	7
adenine and adenosine salvage II	4	15
cis-zeatin biosynthesis	1	9
superpathway of guanosine nucleotides degradation (plants)	2	27
guanosine nucleotides degradation II	1	25
guanosine nucleotides degradation I	2	26
superpathway of purines degradation in plants	6	45
ribose phosphorylation	2	10
pyrimidine ribonucleosides degradation II	2	8
nicotinamide riboside salvage pathway II	1	5
pyrimidine salvage pathway	6	11
purine nucleosides salvage II (plant)	6	13
AtMetExpress overview	0	109
Biochemical pathways: part I	0	466
Trans-zeatin biosynthesis	0	22

Protein Targets (1)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	5.6234	0.0447	17.8581	100.0000	AID485294
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1711518	Growth inhibition of Caenorhabditis elegans N2 L1 larvae under monoxenic condition with Escherichia coli food assessed as reduction in body size at 42 mM incubated for 72 hrs by microscopic method relative to control	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Growth inhibitory effect of D-arabinose against the nematode Caenorhabditis elegans: Discovery of a novel bioactive monosaccharide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	50.61 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.30 (4.65)
Search Engine Demand Index	74.47 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (50.61)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
D-arabinopyranose D-arabinopyranose : D-Arabinose in its pyranose form.	2.13	1	D-arabinose
arabitol arabitol: RN given refers to cpd without isomeric designation. arabinitol : A pentitol that is the sugar alcohol produced by the reduction of arabinose or lyxose. It is found in serum or urine of human infected with Candida albicans.. D-arabinitol : The D-enantiomer of arabinitol.	2.13	1	arabinitol
xylose xylopyranose: structure in first source	2.13	1	D-xylose
arabinose [no description available]	2.13	1	L-arabinose	Escherichia coli metabolite; mouse metabolite
lyxose D-lyxose : Any lyxose having D-configuration.. D-lyxopyranose : The pyranose form of D-lyxose.	2.13	1	D-lyxose
deoxyglucose 2-deoxy-D-glucopyranose : A 2-deoxy-D-glucose that is D-glucopyranose in which the hydroxy group at position 2 has been replaced by a hydrogen.	2.13	1	2-deoxy-D-glucose	metabolite

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0

chemdatabank.com